Semaglutide (Ozempic)
Weekly injection, originally for type 2 diabetes. Strong evidence for HbA1c control and modest-to-significant weight loss. Often the first GLP-1 we start.
Best for: diabetes with weight concern, prediabetes with elevated risk.
WEIGHT LOSS CLINIC
Medically supervised weight loss — with the latest GLP-1 therapies and the safety to use them well.
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have changed what medical weight loss can do. They also change the liver, the pancreas, the heart, and the way you eat. Used responsibly — with the right monitoring — they are powerful. Used carelessly, they are not.
This clinic combines medical weight loss with what really matters underneath: fatty liver reversal, diabetes prevention, lipid control, and lasting habit change.
15-20%
average weight reduction on tirzepatide trials
↓ NAFLD
measurable fatty liver improvement
↓ HbA1c
type 2 diabetes control or remission
Endocrinology Certified
Weill Cornell Medicine — Endocrinology, Diabetes & Metabolism
Why it matters
Weight loss is metabolic medicine. Not just a number on a scale.
For most of my patients, weight is one symptom of a deeper picture: insulin resistance, fatty liver, abnormal cholesterol, prediabetes, even joint pain and disturbed sleep. Treating the weight in isolation rarely works long term.
The new generation of GLP-1 medications — semaglutide and tirzepatide — work because they fix the underlying signaling, not just the willpower. They reduce hunger, slow gastric emptying, improve glucose control, and (importantly for my practice) measurably reduce liver fat.
But they are not magic, and they are not without consequences. Nausea, dehydration, gallbladder issues, pancreatitis, hypoglycemia in combination with insulin — these are real risks if therapy is started or stopped carelessly. A medically supervised program is the difference between a treatment and a side-effect.
Medications we work with
A range of options — chosen for your physiology.
No single medication is right for everyone. Selection depends on your blood sugar status, liver health, cardiovascular risk, kidney function, prior side effects, and budget.
Semaglutide (Wegovy)
The same molecule as Ozempic, dosed specifically for chronic weight management. FDA-approved for adults with BMI ≥27 with comorbidities, or BMI ≥30.
Best for: weight loss as the primary goal, without diabetes.
Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 agonist. In trials, weight loss averaged 15–20% — substantially more than semaglutide. Strong improvements in liver fat and lipids.
Best for: higher BMI, NAFLD with metabolic syndrome, treatment escalation.
Metformin & adjuncts
Foundation therapy for insulin resistance and prediabetes. Inexpensive, well-tolerated, and synergistic with GLP-1s. Often paired with vitamin and micronutrient repletion.
Best for: prediabetes, PCOS, fatty liver, first-line plan.
Liver-directed therapy
For patients with NAFLD or NASH, we layer in vitamin E, pioglitazone in selected cases, and recently approved targeted therapies — alongside weight loss.
Best for: fatty liver patients needing more than lifestyle alone.
Lifestyle program
Medication is half the picture. We pair therapy with structured nutrition guidance, movement targets, sleep, and behavioral support that fits your real life — not a magazine version of it.
Best for: every patient on this program.
Why a gastroenterologist runs this clinic
Read the fatty liver guide
Your liver is the silent partner in any weight-loss conversation.
Most adults carrying excess weight in Pakistan have some degree of non-alcoholic fatty liver disease (NAFLD). It's silent — no pain, no jaundice — until it progresses to NASH, fibrosis, and eventually cirrhosis.
Standard weight-loss clinics don't screen for this. Ours does. Every metabolic patient gets a baseline liver evaluation — enzymes, ultrasound, and FibroScan when indicated — before and during therapy. Weight loss on GLP-1s improves NAFLD measurably; we track that improvement.
When fatty liver is advanced, that changes the program entirely. Better to know.
Built-in monitoring
- Baseline liver enzymes, FibroScan when indicated
- HbA1c, fasting insulin, lipid panel before & after
- Thyroid, vitamin D, and B12 — common silent contributors
- Cardiovascular risk stratification
- Gallstone and pancreatitis vigilance (real GLP-1 risks)
- Hepatitis screening — many adults are unknowingly positive
The program
From first visit to year-long care.
1
Discovery visit
Full metabolic history, prior weight-loss attempts, current medications, and what you actually want from the next year.
2
Baseline workup
Lab panel, ultrasound, FibroScan if indicated, body composition. We know what we're treating before we start.
3
Medication start
If a GLP-1 is the right fit, we begin at a low dose, manage early nausea, and titrate over weeks — not days.
4
Long-term care
Monthly check-ins, regular lab work, plateau planning, and a clear strategy for when (and how) to come off therapy.
Try the free tools
All tools
Before your visit — assess yourself.
Self-assessment tools to help you understand where you stand on weight, liver health, diabetes risk, and cardiac risk. No login. No data stored.
The honest part
GLP-1 medications are not for everyone — and that's how it should be.
If your BMI doesn't meet the threshold, if your goal is to lose 4 kg before a wedding, or if you have a history of pancreatitis or medullary thyroid cancer — these medications are probably not the right choice. We tell patients that openly.
And when they are the right choice, the question changes from "should I take this?" to "how do we use this safely, monitor it well, and build a life that doesn't need it forever?"
That is the work of a medical weight loss clinic. Not selling a prescription.